

HHNSH Lot No. 2210150

Human Liver Microsomes – NASH Donor Pool Untreated, Mixed Gender, Pool of 5 0.5 mL at 20 mg protein / mL

Suspension medium: 250 mM sucrose

Enzyme Activities

Enzyme	Marker Substrate Reaction	[S] (µM)	Rate (pmol/mg protein/min)
CYP1A2	Phenacetin O-dealkylation	80	268 ± 18
CYP2A6	Coumarin 7-hydroxylation	50	586 ± 39
CYP2B6	Bupropion hydroxylation	500	97.9 ± 5.1
CYP2C8	Amodiaquine N-dealkylation	20	1200 ± 100
CYP2C9	Diclofenac 4'-hydroxylation	100	2920 ± 140
CYP2C19	S-Mephenytoin 4'-hydroxylation	400	24.3 ± 2.3
CYP2D6	Dextromethorphan O-demethylation	80	164 ± 11
CYP2E1	Chlorzoxazone 6-hydroxylation	500	2420 ± 90
CYP3A4/5	Testosterone 6β-hydroxylation	250	2190 ± 110
CYP3A4/5	Midazolam 1'-hydroxylation	30	454 ± 19
CYP4A11	Lauric acid 12-hydroxylation	100	1570 ± 70

Values for enzyme activities were determined at a single substrate concentration and are mean ± standard deviation of three or more determinations.

To measure cytochrome P450 (CYP) activity, liver microsomes (50 μ g/mL) were incubated in triplicate at 37 \pm 2°C for 10 minutes in potassium phosphate buffer (50 mM, pH 7.4), containing MgCl₂ (3.0 mM), EDTA (1.0 mM), NADP (1.0 mM), glucose-6-phosphate (5.0 mM), glucose-6-phosphate dehydrogenase (1 Unit/mL) and marker substrate, at the final concentrations indicated. Metabolite formation was determined by validated LC-MS/MS methods with deuterated metabolites as internal standards.

Donor Information

Sample	Gender	Age (Yrs)	Race	Cause of Death
958	М	47	Caucasian	Cerebrovascular accident
1027	F	63	Caucasian	Cerebrovascular accident
1028	F	51	African American	Cerebrovascular accident
1060	М	49	Hispanic	Cerebrovascular accident
1069	М	39	Caucasian	Cerebrovascular accident

Serology information

- Cytomegalovirus: 4 of 5 donors tested positive.
- RPR*: All donors tested negative.
- HIV, HbsAg, and HCV**: All donors tested negative.

^{**} Antibody to Human Immunodeficiency Virus, Hepatitis B Surface Antigen, Antibody to Hepatitis C Virus, respectively.



Store at -80°C

CAUTION: This sample should be considered as a potential biohazard and universal precautions should be followed. Intended for *in vitro* use only.

These data were generated by and are the property of XenoTech. These data are not to be reproduced, published or distributed without the express written consent of XenoTech.

This data sheet serves as a Certificate of Analysis and has been approved by Stephanie Helmstetter, Senior Manager.

Signature and Date:

Stephania Helmstette 12 July 2022**

^{*} Rapid Plasma Reagin